Shots:
- Spero is eligible to receive $40M as an equity investment and ~$80M as development & sales milestones along with royalties on sales of SPR206 in licensed countries. Pfizer gets rights to develop, manufacture & commercialize SPR206 in ex-US & ex-Asia
- As per the 2019 licensing agreement with Spero, Everest Medicines has exclusive rights to develop, manufacture & commercialize SPR206 in Greater China, South Korea & other Southeast Asian countries for MDR gram-negative bacterial infections
- In Jan’21, an agreement was amended for assignment of relevant SPR206 patents to Everest in the licensed territories while agreement b/w Spero & Pfizer have no impact on Everest’s rights for SPR206
Click here to read full press release/ article | Ref: PR Newswire | Image: Cowen
The post Spero Therapeutics Enters into a License Agreement with Pfizer for SPR206 to Treat MDR Gram Negative Infections first appeared on PharmaShots.
